Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 276

Similar articles for PubMed (Select 23861242)

1.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

PMID:
23861242
2.

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.

Ware RE, Schultz WH, Yovetich N, Mortier NA, Alvarez O, Hilliard L, Iyer RV, Miller ST, Rogers ZR, Scott JP, Waclawiw M, Helms RW.

Pediatr Blood Cancer. 2011 Dec 1;57(6):1011-7. doi: 10.1002/pbc.23145. Epub 2011 Aug 8.

3.

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Ware RE, Helms RW; SWiTCH Investigators.

Blood. 2012 Apr 26;119(17):3925-32. doi: 10.1182/blood-2011-11-392340. Epub 2012 Feb 7.

4.

Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.

Greenway A, Ware RE, Thornburg CD.

Am J Hematol. 2011 Apr;86(4):357-61. doi: 10.1002/ajh.21986.

PMID:
21442640
5.

Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.

Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE; SWiTCH Study Investigators.

Am J Hematol. 2012 Feb;87(2):221-3. doi: 10.1002/ajh.22228. Epub 2011 Nov 25.

PMID:
22120913
6.

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Wang WC, Dwan K.

Cochrane Database Syst Rev. 2013 Nov 14;11:CD003146. doi: 10.1002/14651858.CD003146.pub2. Review.

PMID:
24226646
7.

Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.

Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH.

J Pediatr. 2004 Sep;145(3):346-52.

PMID:
15343189
8.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B; study CICL670A2201 investigators.

Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

9.

Neuropathy, neuropathic pain, and sickle cell disease.

Ballas SK, Darbari DS.

Am J Hematol. 2013 Nov;88(11):927-9. doi: 10.1002/ajh.23575. Epub 2013 Oct 11. No abstract available.

PMID:
23963922
10.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
11.
12.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Review.

PMID:
20687088
13.

Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.

Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE; SWiTCH Investigators.

Blood. 2014 Aug 7;124(6):891-8. doi: 10.1182/blood-2013-12-545186. Epub 2014 Jun 9.

PMID:
24914136
14.

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22.

15.

Gated myocardial perfusion scintigraphy in children with sickle cell anemia: correlation with echocardiography.

Hallioglu O, Ceylan Gunay E, Unal S, Erdogan A, Balci S, Citirik D.

Rev Esp Med Nucl. 2011 Nov-Dec;30(6):354-9. doi: 10.1016/j.remn.2011.02.003. Epub 2011 Mar 31. English, Spanish.

16.

Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.

Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE; Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) Trial Investigators.

Br J Haematol. 2015 Apr;169(2):262-6. doi: 10.1111/bjh.13280. Epub 2015 Jan 22.

PMID:
25612463
17.

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.

Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19.

18.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
19.

Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).

Sumoza A, de Bisotti R, Sumoza D, Fairbanks V.

Am J Hematol. 2002 Nov;71(3):161-5.

PMID:
12410569
20.

Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.

Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.

Hemoglobin. 2014;38(5):345-50. doi: 10.3109/03630269.2014.940462. Epub 2014 Jul 22.

PMID:
25051423
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk